Related Experiment Videos
Association between midazolam premedication and deep sedation following general anesthesia in pediatric patients: a
Aurelia Zodl1, Toby N Weingarten1, Darrell R Schroeder1
1Department of Anesthesiology and Perioperative Medicine and Division of Clinical Trials and Biostatistics (Schroeder), Mayo Clinic, 200 First St SW, Rochester, 55905, MN, US.
Insights
Oral midazolam increases the risk of deep sedation in pediatric patients aged 2-11 years, particularly after shorter procedures. This deep sedation did not lead to adverse outcomes.
Area of Science:
- Anesthesiology and Perioperative Medicine
- Pediatric Sedation Management
- Pharmacology of Sedative Agents
Background:
- Midazolam is commonly used for premedication in pediatric patients.
- The route of midazolam administration (oral vs. intravenous) may influence postoperative sedation levels.
- Understanding sedation risks is crucial for patient safety in the postanesthesia care unit.
Purpose of the Study:
- To investigate whether oral (PO) versus intravenous (IV) midazolam premedication is associated with an increased risk of deep sedation in pediatric patients.
- To identify patient and procedural factors associated with deep sedation after midazolam premedication.
Main Methods:
- Retrospective review of medical records for pediatric patients (2-17 years) who received midazolam premedication from May 2018 to December 2023.
- Stratification of patients based on midazolam administration route (PO vs. IV).
- Assessment of sedation levels using the Richmond Agitation-Sedation Scale, with deep sedation defined as ≤ -4.
- Application of Inverse Probability of Treatment Weighting (IPTW) to adjust for confounding variables and assess the association between administration route and deep sedation.
Main Results:
- Out of 5245 pediatric patients, 11.6% experienced deep sedation.
- Deep sedation was significantly more frequent with oral midazolam compared to intravenous midazolam (13.7% vs. 5.3% unadjusted; 13.3% vs. 6.6% adjusted; OR 2.17).
- The risk of deep sedation was higher in younger children (2-11 years) and after shorter surgical procedures (≤ 1 hour), with no significant difference observed in adolescents or after longer procedures.
- No sedation-related adverse events were reported.
Conclusions:
- Oral midazolam is a significant factor contributing to postoperative deep sedation in pediatric patients aged 2-11 years, especially following brief surgical interventions.
- The increased risk is potentially linked to insufficient drug elimination time during shorter procedures.
- Despite the increased incidence, deep sedation following midazolam premedication was not associated with adverse outcomes.
Purpose:
We examined if midazolam premedication via oral (PO) vs. intravenous (IV) route in pediatric patients was associated with risk for deep sedation in the postanesthesia care unit.
Methods:
Medical records from May 2018 to December 2023 of patients aged 2-17 years premedicated with midazolam were reviewed and stratified according to administration route. Sedation level was classified using the Richmond Agitation-Sedation Scale: deeply sedated (≤ - 4) or not (≥ - 3). Inverse probability of treatment weighting (IPTW) analysis was performed to assess whether midazolam administration route was associated with postoperative deep sedation.
Results:
Among 5245 pediatric patients, 608 (11.6%) experienced deep sedation. In unadjusted analyses, deep sedation occurred more frequently with PO than IV midazolam (13.7% vs. 5.3%, P < 0.001). After IPTW adjustment, this association remained significant (13.3% vs. 6.6%; OR 2.17, 95% CI 1.35-3.48; P = 0.001). The incidence of deep sedation decreased with increasing age and surgical duration. In IPTW-adjusted analyses, route-related differences were significant in patients aged 2-5 years (17.0% vs. 7.3%, P = 0.013) and 6-11 years (12.3% vs. 6.2%, P = 0.018), but not in adolescents (P = 0.632). Deep sedation rates were higher after procedures lasting ≤ 1 h (20.0% vs. 7.6%, P = 0.018), but not for longer procedures. No sedation-related adverse events were observed.
Conclusions:
Oral midazolam is a key driver of postoperative deep sedation in premedicated patients aged 2-11, especially following shorter procedures likely due to limited drug elimination time. Notably, deep sedation was not linked to adverse outcomes.
Related Concept Videos
Parenteral Anesthetics: Overview
Stages of General Anesthesia
General Anesthesia: Overview
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...
Inhalational Anesthetics: Overview
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...